Corient Private Wealth LP Invests $323.04 Million in Stryker Corporation $SYK

Corient Private Wealth LP bought a new position in shares of Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 1,748,739 shares of the medical technology company’s stock, valued at approximately $323,035,000.

Other institutional investors have also bought and sold shares of the company. Gables Capital Management Inc. bought a new position in shares of Stryker during the second quarter valued at $25,000. Kilter Group LLC acquired a new stake in shares of Stryker in the 2nd quarter valued at $25,000. Godfrey Financial Associates Inc. bought a new stake in shares of Stryker in the 4th quarter worth about $26,000. Sankala Group LLC bought a new stake in shares of Stryker in the 4th quarter worth about $26,000. Finally, Compass Financial Management LLC acquired a new stake in shares of Stryker during the 2nd quarter worth about $27,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Down 0.2%

NYSE SYK opened at $330.08 on Thursday. The stock has a market capitalization of $126.61 billion, a P/E ratio of 34.21, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock has a fifty day moving average of $328.37 and a 200-day moving average of $331.72.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is presently 36.48%.

Analysts Set New Price Targets

Several brokerages recently issued reports on SYK. JPMorgan Chase & Co. cut their price target on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a report on Friday, July 31st. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $361.00 price objective on shares of Stryker in a research note on Friday, May 1st. Truist Financial lifted their target price on shares of Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research note on Friday, July 31st. Wells Fargo & Company reduced their target price on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Finally, BMO Capital Markets began coverage on Stryker in a research report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average price target of $386.28.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 300,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the sale, the director directly owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. The trade was a 11.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Debra King sold 826 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares in the company, valued at $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 351,267 shares of company stock worth $118,197,701. Company insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.